anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Third space endoscopy (TSE) or sub-mucosal endoscopy using a mucosal flap valve (SEMF) enables the endoscopist to operate in the deeper layers of the gastrointestinal tract or gain access to the mediastinal/peritoneal cavity for natural orifice transoral endoscopic surgery (NOTES). TSE procedures are essentially endoscopic surgical procedures with a variable learning curve. Adverse events (AEs) during TSE are specific and follow a certain pattern across the spectrum of TSE procedures. These can be broadly categorized according to either type of AE, time of presentation relative to the procedure or according to degree of severity. Three major categories of AEs encountered during TSE include insufflation related AEs, mucosal injuries (MIs) and bleeding. Other relevant AEs include infectious complications, aspiration pneumonia, post-procedural chest/abdominal pain, atelectasis, cardiac arrhythmias, pleural effusion and pulmonary embolism. Reported incidence of AEs during TSE procedures varies according to the type and complexity of procedure. Acquaintance regarding potential risk factors, technical tips and precautions, alarm signs for early recognition, assessment of degree of severity, morphological characterization of AEs and finally, expeditious selection of appropriate management strategy are crucial and imperative for successful clinical outcomes. The current review discusses the current evidence and practical guidelines for prevention, early detection and management of TSE-related AEs.
Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). At the end of surgery, 30 mL bupivacaine 0.25% will be injected subcutaneously in the surgical wound (15 mL on the upper and lower sides) by the obstetrician before skin suturing. Sham procedure will be performed after surgery. Standard analgesia (ketorolac and paracetamol) and fentanyl patient-controlled analgesia will be administered postoperatively.
PURPOSE:A cosmetic that contains a wax which occurs in oil from sunflower seeds and has good luster, high stability to oxidation, good smell, no irritation to skin and high melting point. CONSTITUTION:The objective cosmetic contains a wax which has been discarded as a water in the production of salad oil from sunflower seeds. The wax is obtained by concentration of an oil fraction of high wax content resulting from fractionation such as wintering by means of separation with a polymeric membrane or extractive fractionation with solvents such as acetone or methyl ethyl ketone. The resultant wax has better luster, color and smell than carnauba wax. Further, it is well spreadable on skins and high in its melting point, because it is mainly composed of monoester from saturated fatty acid of 20 or more carbon atoms and higher saturated alcohol. Therefore, the wax raise the melting point of stick cosmetics with temperature stability given.
Paid carers (n=50) of people with intellectual disabilities in England, who use the internet, will be invited to take part in an online survey. A subgroup of paid carers (n=7) will be asked if they would like to take part in a focus group.
PURPOSE:To obtain an antimycoplasmic agent exhibiting strong activity against mycoplasma resistant to tylosin which is a remedy for mycoplasmosis of animal, by using a tropolone having antibacterial activity as an active component. CONSTITUTION:A tropolone of formula I (R1 is hydroxy, aliphatic acyloxy, arylacyloxy, arylsulfonyloxy, carboxyalkyloxy, benzoylalkyloxy, alkenyloxy, 1,3-dihydro-3-oxo-1-isobenzofuranyloxy, etc.; R2 is H, halogen, hydroxy, etc.), its derivative or its salt is used as an active component of the objective agent. The active component is mixed with a carrier, a flavor, a colorant, a preservative, etc., and is used in the form of powder, liquid, etc. Among the compounds of formula I, the compounds of formula II (R1 is 1-carboxyethyloxy, etc.) are novel.
UNLABELLED: Zellweger syndrome is an autosomal recessive disease within the spectrum of peroxisome biogenesis disorder manifesting in the neonatal period with profound dysfunction of the central nervous system, liver and kidney. Common clinical presentations include hypotonia, seizure, hepatomegaly, craniofacial dysmorphism and early death. Mutation in one of the PEX genes coding for a peroxisome assembly protein creates a functionally incompetent organelle causing accumulation of very long chain fatty acids in various organs. Here we report the case of a 5-month-old male presented at birth with hypotonia, poor feeding, gross congenital anomalies and later during early infancy with failure to thrive, several episodes of seizures, aspiration due to feeding difficulties and recurrent severe pneumonia. A whole genomic sequencing brought us to the final diagnosis of Zellweger syndrome. Despite an absence of treatment options, prompt diagnosis of Zellweger syndrome is important for providing appropriate symptomatic care, definitive genetic testing and prenatal counselling.
KEYWORDS: case reports; mutation; neonate; Zellweger syndrome.
The COPD app consisted of an 8 week self-management program. The app had three views: timeline, information page, and contact page. The timeline was classified in 8 weeks, and each week included the lung exacerbation plan, daily and extra medication, information and education and questionnaires. The first week also included a video of a pulmonologist explaining the purpose of the app and additional information about the functionalities of the COPD app. A video consultation was planned after after 4 weeks and a face-to-face consultation after 8 weeks.
The invention relates to the technical field of traditional Chinese medicines, and particularly discloses healthcare tea with a blood lipid reducing function. The healthcare tea comprises, by weight, 40-60 parts of dendrobium officinale leaves, 20-30 parts of flos notoginseng, 5-15 parts of radix astragali and 5-15 parts of radix salviae miltiorrhizae. A method for preparing the healthcare tea includes mixing the dendrobium officinale leaves, the radix astragali and the radix salviae miltiorrhizae with one another to obtain mixtures, carrying out reflux extraction on the mixtures by the aid of water by 1-5 times to obtain extract liquid, concentrating the extract liquid and freezing and drying the extract liquid to obtain extract powder; mixing the extract powder and the flos notoginseng with each other to obtain the healthcare tea with the blood lipid reducing function. The quantity of the water is 5-10 times that of the mixtures. The mixtures are subjected to reflux extraction for 0.5-3 h in each reflux extraction procedure. The healthcare tea has the advantages that a certain blood lipid reducing effects can be realized by the healthcare tea, and the healthcare tea is free of side effects even after people drink the healthcare tea for a long time.
The purpose of this study is to collect long-term safety information on infliximab (Remicade) from patients who participate in research studies using those drugs. All patients in these studies are being asked to participate in this long-term safety follow-up study which will provide important information about the study drug. The long-term effect of the study drug on survival, serious infections, new malignancies and new autoimmune diseases will be measured from data collected over a 5-year period. Additional information about possible delayed allergic reactions (possible fever, rash, fatigue, joint pain) will also be collected if you received infliximab (Remicade) after the end of the primary study. Study participation in this research study is 5 years after the end of the primary study. Questionnaires will be completed about patient's health and the occurrence of these safety events at intervals of 6 months, 1 year, 2 years, 3 years, 4 years and 5 years after patients complete participation in the primary study.
Previous studies have suggested that diabetic patients should align their food and nutrient intake with their biological metabolic rhythm. However, the optimal timing of coffee consumption to prevent the development of chronic kidney disease (CKD) in diabetic patients remains unknown. This study aims to examine the association between the amount and timing of coffee consumption and CKD prevalence in diabetic patients. We recruited a nationally representative sample of 8564 diabetes patients from NHANES (National Health and Nutrition Examination Survey) from 2003 to 2018. Coffee intake was assessed using a 24 hour dietary recall and categorized into different time periods throughout the day: dawn-to-forenoon (5:00 a.m. to 8:00 a.m.), forenoon-to-noon (8:00 a.m. to 12:00 p.m.), noon-to-evening (12:00 p.m. to 6:00 p.m.), and evening-to-dawn (6:00 p.m. to 5:00 a.m.). Logistic regression models were used to assess the association between the amount and timing of coffee consumption and the prevalence of CKD in diabetic patients. After adjusting for potential confounders, diabetic patients who had the status of coffee consumption throughout the day had a lower prevalence of CKD compared to those who did not (OR: 0.89, 95% CI: 0.80-0.99). In terms of the timing of coffee consumption, diabetic patients who consumed coffee or had higher levels of coffee consumption from dawn-to-forenoon had a lower incidence risk of CKD (OR: 0.87, 95% CI: 0.77-0.98; OR: 0.83, 95% CI: 0.70-0.98). Conversely, diabetic patients who consumed higher levels of coffee during the noon-to-evening and evening-to-dawn periods had an increased incidence risk of CKD (OR: 1.35, 95% CI: 1.07-1.71 and OR: 1.28, 95% CI: 1.01-1.64, respectively). These observations remained robust across different participant subtypes. Our results indicated that diabetic patients who consumed coffee from dawn-to-forenoon had a lower risk of developing CKD, while those who consumed coffee from noon-to-evening or evening-to-dawn had an increased risk.
Maintenance treatment with risankizumab 180 mg administered subcutaneously (SC) every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
A sponge containing Dead Sea mud and minerals in solid or viscous (gel) state. The mud and minerals in the sponge do not constitute a separate and independent unit within the sponge, but rather are distributed throughout the sponge and there is no clear and defined boundary between the sponge and the mud and minerals. The method, subject of the invention, enables to inject liquid mud and minerals into a sponge and make them solid or viscous. The method comprises the following operations: A tubule with holes is inserted into the sponge. A predetermined dose of liquid mud and minerals is pumped through the tubule into the sponge, and is distributed throughout most of the sponge. The liquids in the sponge are dried to obtain a sponge that contains solid or viscous mud and minerals.
A surgical instrument includes a rotatable electrical coupling assembly having a first part and a second part that electrically couple and rotate relative to each other. The second part is carried by and rotates with a tube collar coupled to a transducer. A portion of the transducer is inserted through an aperture of the second part, but does not contact the second part. The first part of the assembly may electrically couple to the second part via pogo pins, brush contacts, or ball bearings. Alternatively, the first part may comprise conductive channels formed in the casing. The second part may comprise a rotatable drum with a conductive trace. In some versions, one or more components may comprise MID components. In another version, the rotatable electrical coupling assembly comprises a rotatable PC board and brush contact. Further still, a circuit board may be provided with the transducer inside a transducer casing.
A stent comprising tubular stent matrixes whose diameter is extendable and flexible polymer layers covering the stent matrixes. The polymer layers adhere to and cover the entire external surfaces of the stent matrixes. The adhesion of and covering with the flexible polymer layers are not limited to the outer circumference surfaces of the stent matrixes and are accomplished over the entire external surfaces of the stent matrixes. Therefore, the problems of metal allergy, cell stimulation by metals and rusting can be thoroughly avoided. Further, the inner circumference surface of stent consists of a smooth surface covered with polymer layer, so that the formation of blood clot can be satisfactorily suppressed. Still further, the problem of dislocation between stent matrixes and polymer layers upon stent extension can be avoided to thereby enable maintaining the positional relationship between stent matrixes and polymer layers even after stent extension.
Oral carcinogenicity studies were conducted in mice and rats. In an oral carcinogenicity study conducted in female mice, sirolimus administered once daily for 86 weeks was associated with a statistically significant increase in malignant lymphoma at all dose levels compared with control animals. In a second oral mouse carcinogenicity study, sirolimus-related hepatocellular adenoma and carcinoma were induced in male mice. In an oral carcinogenicity study conducted in rats with sirolimus there were no significant findings.

Sirolimus was not genotoxic in the in vitro bacterial reverse mutation assay, the Chinese hamster ovary cell chromosomal aberration assay, the mouse lymphoma cell forward mutation assay, or the in vivo mouse micronucleus assay.

Fertility was decreased in both male and female rats following oral administration of sirolimus 2.0 and 0.5 mg/kg, respectively. In male rats, atrophy of testes, epididymides, prostate, seminiferous tubules and/or reduced sperm counts were observed. In female rats, decreased ovarian and uterine weights and decreased implantation were observed. Testicular tubular degeneration was also seen in a 4-week intravenous study of sirolimus in monkeys at 0.1 mg/kg.
As part of the induction, patients will be given 2 milligrams of propofol per kilogram (mg/kg) of body weight. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL.
Dexamethasone 10 mg is administered before anesthesia induction. Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
Participants received 15 sessions (15 daily session - Monday to Friday) of active rTMS over the 'hotspot" M1 area of the unaffected hemisphere leading to a response in the contralateral thenar muscle using Visor2-navigation system and MagstimRapid -magnetic stimulator. Low frequency rTMS was applied at 80-90% resting motor threshold (rMT) intensity, 1 Hz, 600+600 pulses, inbetween 10 minutes break. Intensity was increased after each 2-3 treatment to keep motor threshold 90%.
A solid oral dosage form comprising therapeutically effective amounts of acetaminophen and a non-steroidal anti-inflammatory drug (NSAID) as active ingredients. The dosage form may contain binder material to cohesively bind the ingredients. The dosage form may further comprise a disintegrant to ensure effective disintegration in the gastrointestinal tract. For example, the solid oral dosage form may be a single tablet that contains about 1,000 mg of acetaminophen and about 400 mg of ibuprofen. In another example, the solid oral dosage form may be a single tablet that contains about 650 mg of acetaminophen and about 400 mg of ibuprofen. This invention may be particularly suitable in the management of dental pain.
PURPOSE:To provide the titled drug containing tocopherylquinone, free from the hormone-like side effects, and having mild effect to the skin and excellent remedying effect to pimple. CONSTITUTION:The titled dermatic drug for the remedy of pimple and having the above effects is prepared by compounding about 0.001-2wt% tocopherylquinone of formula in a drug for external application, e.g. cream, ointment, lotion, etc. The drug may contain, in addition to the above component, an antibacterial agent such as hexachlorophene, a drug such as vitamin A acid, a photosensitive compound, salicylic acid, zinc or its compound, lactic acid, etc., a kelatolytic agent, etc. and if necessary, an oil, a surface active agent, water, ethanol, a humectant, a thicknener, a perfumery, a pigment, etc. to an extent not to lower the above effect. The rate of application depends upon the symptom, however, usually about 0.1mg-0.5g per dose and one-several doses a day by applying to the rash.
The study proposed is a 22 to 23 day, double-blind, placebo-controlled crossover study in 60 male and female moderate to heavy alcohol users who are Asp40 positive and negative. Subjects will undergo a 6 to 7-day cycle taking the first study drug (naltrexone or placebo) with an alcohol self-administration visit in the laboratory bar on the 6th or 7th day of drug. The first alcohol self-administration visit is followed by an 8 to 9 day washout period. Subjects then cross over to repeat the cycle while taking the other drug (placebo or naltrexone). On the final day (either day 8 or 9) of the first study drug cycle, the subject will undergo functional imaging (fMRI) at the WBIC. There will be at least one day in between the 'lab bar' and the fMRI scan. The first fMRI visit is followed by a 5-6 day washout period. Subjects then cross over to repeat the cycle while taking the other drug (placebo or naltrexone). Subjects will keep daily diaries of alcohol and medication use throughout the study.
Post-operative delirium is a common occurrence in older adults. Post -operative delirium has been associated with cognitive decline after hospitalization. Developing perioperative management strategies to prevent delirium may also reduce potential cognitive decline in older adults after surgery. The choice and dose of anesthetic and sedative drugs are known risk factors in the development of delirium. Excessive doses of anesthetic and sedation drugs during surgery have been associated with poor outcomes that occur after surgery. Currently depth of anesthesia can be measured by an additional monitoring technique called Bispectral Index (BIS).

The purpose of this study is to determine if light sedation with spinal anesthesia reduces the incidence of delirium compared to receiving general anesthesia during spinal surgery in older adults. Previous studies have shown that using light sedation and spinal anesthesia during surgery may reduce the incidence of delirium up to 50%.
Chemotherapy-induced peripheral neuropathy (CIPN) is among the most prevalent and debilitating adverse effects of cancer treatment. CIPN increase risk of falls and impair physical function and quality of life (QOL). Physical therapy improves the CIPN symptoms, quality of life and physical function in cancer patients after chemotherapy. Telerehabilitation technologies such as telephone and video conferencing, have the capability of bringing services into the survivors' home and manage the symptoms without needing to have direct physical contact with the hospital or clinic services. The aim of this study is to determine the comparative effects of telerehabilitation versus clinical rehabilitation on neuropathic pain, physical function and quality of life.

This study will be a randomized clinical trial that will conducted at Gujranwala institute of Nuclear Medicine hospital in which sixty-six cancer patient who will sustain grade 3 and grade 4 of European Organization for Research and Treatment of Cancer Quality of life-Chemotherapy Induced Peripheral Neuropathy Questionnaire (EORTC-QLQ-CIPN20)will randomly allocated to Group A(n=33)who will receive Telerehabilitation and Group B (n=33) who will receive clinical rehabilitation using the computer generated method. The sample size calculated for this trial will be 66. Interventions will be given in both groups for 60 minutes for 12 weeks (3times per week).10 minutes for Nerve Gliding exercises ,20 minutes for Balance training and 20 minutes forResistance training (using Therapeutic band).European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) will be used to assess quality of life. Berg balance scale for balance and Manual Muscle testing for muscle strength. The data will be entered and analyzed using SPSS 26. Statistical significance will be set at p=0.05. Normality of data will be assessed through Kolmogorov-Smirnov test. Assessment will be carried out at baseline,6th week, 12th week after discontinuation of treatment and 18th week follow up. For between group analysis of parametric data Independent T test will be used, while Mann Whitney test will be applied for non-parametric data. For within group comparison repeated measure ANOVA will be used, for non-parametric data, Friedman ANOVA will be applied.
Mucormycosis is a rare opportunistic infection caused by Mucorales fungi. Cutaneous mucormycosis typically present as chronic indolent infection, whereas rhino-orbital mucormycosis is rapidly progressive disease often invade the adjacent cerebral tissue associated with high mortality. This case represents the atypical clinical history of rhino-orbital-cutaneous mucormycosis. The patient was presented with a right orbital cellulitis associated with an extensive multiple suppurative deep cutaneous infection and worsening headache. The skin lesion was initiated from a localized abscess at the right periorbital area nine months before admission. Suspicion of fungal infection was raised after weeks of non-responsive antibiotics treatment. Aggressive treatment with exoneration of the right eye and surgical debridement was undertaken. Periodic acid Schiff staining from healthy periorbital tissue revealed ribbon-like hyphae with pauciseptate and 90° branching identified as Mucoraceaefamily. The resolution was seen after four weeks of antifungal treatment with Amphotericin B.
The invention is directed to human homologs of nucleic acid molecules derive d from rat brain and programmed cell death expression libraries. These molecul es can constitute microarrays of expressed sequences useful for analyzing gene expression in various biological contexts, including development, differentiation, and disease, both in vivo and in vitro. The nucleic acid molecules are useful for diagnosis, treatment, and drug discovery. The nucle ic acid molecules are useful for creating microarrays for transcriptional profiling. The invention further provides peptides encoded by the nucleic ac id molecules, useful for methods of diagnosis, treatment, and drug discovery. T he invention specifically relates to nucleic acid molecules involved in programmed cell death.
This is a single-arm trial. The intervention itself proceeds as follows: After approximately 5 minutes of warmup subjects will perform 10 intervals of VIIT: 30 seconds of vigorous intensity exercise followed by 60 seconds of rest. Rated Perceived Exertion (RPE) will be rated by 15-point Borg scale; should correspond to HR/10 at end of each interval. The subject will self-adjust the intensity of the exercise bouts and will be encouraged by the researcher to achieve the desired intensity. The exercise session will finish with a short cool-down period and will last no more than 25 minutes in total.